CY1113578T1 - 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια - Google Patents

2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Info

Publication number
CY1113578T1
CY1113578T1 CY20131100076T CY131100076T CY1113578T1 CY 1113578 T1 CY1113578 T1 CY 1113578T1 CY 20131100076 T CY20131100076 T CY 20131100076T CY 131100076 T CY131100076 T CY 131100076T CY 1113578 T1 CY1113578 T1 CY 1113578T1
Authority
CY
Cyprus
Prior art keywords
nitroimidazo
dihydro
oxazolia
general formula
provides
Prior art date
Application number
CY20131100076T
Other languages
Greek (el)
English (en)
Inventor
Hidetsugu Tsubouchi
Hirofumi Sasaki
Hideaki Kuroda
Motohiro Itotani
Takeshi Hasegawa
Yoshikazu Haraguchi
Takeshi Kuroda
Takayuki Matsuzaki
Kuninori Tai
Makoto Komatsu
Makoto Matsumoto
Hiroyuki Hashizume
Tatsuo Tomishige
Yuji Seike
Masanori Kawasaki
Takumi Sumida
Shin Miyamura
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1113578T1 publication Critical patent/CY1113578T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CY20131100076T 2002-10-11 2013-01-25 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια CY1113578T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11
EP03754085A EP1555267B1 (en) 2002-10-11 2003-10-10 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES

Publications (1)

Publication Number Publication Date
CY1113578T1 true CY1113578T1 (el) 2016-06-22

Family

ID=32089299

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100076T CY1113578T1 (el) 2002-10-11 2013-01-25 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CY2014041C CY2014041I2 (el) 2002-10-11 2014-09-24 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2014041C CY2014041I2 (el) 2002-10-11 2014-09-24 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια

Country Status (26)

Country Link
US (1) US7262212B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1555267B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4186065B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100723847B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (4) CN101172981A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (4) AR041198A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003272979B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C053I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0314344B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2497569C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1113578T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1555267T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2400179T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1400046I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92517I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05003674A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY139244A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL404913A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1555267E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2326121C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1555267T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI347946B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA83200C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004033463A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200501033B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
WO2004035547A1 (ja) 2002-10-15 2004-04-29 Otsuka Pharmaceutical Co., Ltd. 1位置換―4―ニトロイミダゾール化合物及びその製造法
DE602004017037D1 (de) * 2003-10-31 2008-11-20 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 2,3−ジヒドロイミダゾ[2,1−b]オキサゾ−ル化合物
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
AU2005228289B2 (en) 2004-03-31 2008-01-10 Nippon Soda Co., Ltd. Cyclic amine compound and pest control agent
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
WO2007002057A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
DE602006018617D1 (de) * 2005-07-28 2011-01-13 Otsuka Pharma Co Ltd Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
TWI368509B (en) * 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
EP1932844B1 (en) * 2005-10-06 2015-09-02 Nippon Soda Co., Ltd. Cross-linked cyclic amine compounds and agents for pest control
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
AU2006333522A1 (en) 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
JP2009526773A (ja) * 2006-02-13 2009-07-23 ラボラトワール セローノ ソシエテ アノニム 細菌感染症治療のためのスルホンアミド誘導体
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd N−(2,3−エポキシ−2−メチルプロピル)フタルイミドの製造法
CA2678577A1 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
AR070301A1 (es) * 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
JP5470557B2 (ja) * 2007-07-26 2014-04-16 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤の合成
US7884114B2 (en) * 2007-08-15 2011-02-08 Glaxo Group Limited Compounds
US20100222349A1 (en) * 2007-10-16 2010-09-02 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
EP2229368A1 (en) 2007-12-11 2010-09-22 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (en) 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2252598A2 (en) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5730021B2 (ja) * 2008-02-15 2015-06-03 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤としてのシクロアルキルラクタム誘導体
CA2718264A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
NZ587096A (en) * 2008-03-26 2011-11-25 Global Alliance For Tb Drug Dev Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
EP2291371B1 (en) 2008-05-01 2015-06-10 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CN102089300B (zh) * 2008-05-01 2014-06-18 生命医药公司 11β-羟基类固醇脱氢酶1的环状抑制剂
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
JP5525515B2 (ja) * 2008-08-21 2014-06-18 デイナミート ノーベル ゲゼルシャフト ミット ベシュレンクテル ハフツング エクスプロジーフシュトッフ− ウント ジステームテヒニク 2−ハロ−4−ニトロイミダゾール及びその中間体の製造方法
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
US20100331320A1 (en) * 2009-04-30 2010-12-30 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 1,3−オキサジナン−2−オン構造に基づく11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
AU2010278777B2 (en) * 2009-07-31 2015-05-07 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
KR101738868B1 (ko) * 2009-07-31 2017-05-23 글로벌 알리앙스 포 티비 드럭 디벨롭먼트 니트로이미다조옥사진 및 니트로이미다조옥사졸 동족체 및 이들의 용도
US20120219500A1 (en) 2009-10-26 2012-08-30 Fujifilm Ri Pharma Co., Ltd. Diagnostic agent for infectious diseases
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 置換5、6及び7員複素環、そのような化合物を含有する医薬及びそれらの使用
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
EP3052503B1 (en) 2013-10-04 2018-10-24 Council of Scientific & Industrial Research 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
EP3209669B1 (en) * 2014-10-21 2018-11-07 Council of Scientific and Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
RU2675622C1 (ru) * 2015-01-29 2018-12-21 Медшайн Дискавери Инк. Производное нитроимидазола против туберкулеза легких
US10252995B2 (en) 2015-03-27 2019-04-09 Otsuka Pharmaceutical Co., Ltd. Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
JP6905506B2 (ja) 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
BR112019001163A2 (pt) * 2016-07-22 2019-04-30 Medshine Discovery Inc. cristal e sal de nitroimidazol e método de fabricação do mesmo
SI3668879T1 (sl) * 2017-08-16 2022-04-29 Glaxosmithkline Intellectual Property Development Limited Nove spojine
EP3804720A4 (en) 2018-06-11 2022-02-09 Otsuka Pharmaceutical Co., Ltd. DELAMANID CONTAINING COMPOSITION
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
JPWO2024024938A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-07-29 2024-02-01
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) * 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Also Published As

Publication number Publication date
EP2570418A3 (en) 2013-07-03
WO2004033463A1 (ja) 2004-04-22
TW200420568A (en) 2004-10-16
CN1705670A (zh) 2005-12-07
KR20050061473A (ko) 2005-06-22
DK1555267T3 (da) 2013-02-11
MY139244A (en) 2009-09-30
AU2003272979A1 (en) 2004-05-04
US7262212B2 (en) 2007-08-28
SI1555267T1 (sl) 2013-05-31
CN101172981A (zh) 2008-05-07
ES2400179T3 (es) 2013-04-08
EP1555267A1 (en) 2005-07-20
CN102532162B (zh) 2015-05-27
AR086485A2 (es) 2013-12-18
BRPI0314344B8 (pt) 2021-05-25
HK1085463A1 (zh) 2006-08-25
BR0314344A (pt) 2005-07-12
ZA200501033B (en) 2006-06-28
CY2014041I1 (el) 2016-07-27
PT1555267E (pt) 2013-01-29
AU2003272979B2 (en) 2009-07-23
AR089950A2 (es) 2014-10-01
FR14C0066I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-10-17
AR041198A1 (es) 2005-05-04
TWI347946B (en) 2011-09-01
CN101255170A (zh) 2008-09-03
RU2005114017A (ru) 2006-01-20
CY2014041I2 (el) 2016-07-27
FR14C0066I2 (fr) 2015-05-22
HK1171018A1 (en) 2013-03-15
EP2570418A2 (en) 2013-03-20
PL217919B1 (pl) 2014-09-30
RU2326121C3 (ru) 2021-09-17
US20060094767A1 (en) 2006-05-04
PL409525A1 (pl) 2014-11-10
RU2326121C2 (ru) 2008-06-10
UA83200C2 (en) 2008-06-25
MXPA05003674A (es) 2005-06-08
BE2014C053I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-08-30
CA2497569C (en) 2011-05-24
HUS1400046I1 (hu) 2017-04-28
KR100723847B1 (ko) 2007-05-31
CA2497569A1 (en) 2004-04-22
JP4186065B2 (ja) 2008-11-26
LU92517I2 (fr) 2014-10-13
JP2004149527A (ja) 2004-05-27
PL376157A1 (en) 2005-12-27
EP1555267A4 (en) 2010-08-18
BRPI0314344B1 (pt) 2019-11-26
AR091771A2 (es) 2015-02-25
EP1555267B1 (en) 2013-01-16
CN102532162A (zh) 2012-07-04
PL404913A1 (pl) 2013-09-30
CN100366624C (zh) 2008-02-06

Similar Documents

Publication Publication Date Title
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
DK1385515T3 (da) Spiropyrazole forbindelser
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
CY1114083T1 (el) Συνδυασμος μιας ενωσης της 5-φαινυλοθειαζολης ως αναστολεας της κινασης pi3 με ενα αντιφλεγμονωδες, βρογχοδιασταλτικο ή αντιισταμινικο φαρμακo
CY1113362T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
HRP20120323T1 (en) Diarylhydantoin compounds
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
UY28290A1 (es) Compuestos farmacéuticos novedosos
MY132698A (en) Herbicidal composition
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
ATE452882T1 (de) Herstellung von quetiapin
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
RS51146B (sr) Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
GB0521508D0 (en) Organic compounds
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
PA8543701A1 (es) Fenil-heterociclil-eteres
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
BR0214445B1 (pt) processos para a produção de compostos.